ArticleThoracic cancer2024

Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer.

Toshiyuki Sumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.